Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
about
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assayMET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Promise and challenges on the horizon of MET-targeted cancer therapeuticsMET in human cancer: germline and somatic mutations.Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.HGF-MET as a breast cancer biomarker.Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
P2860
Q26748581-75F95D72-FE06-444A-B694-1AAEE864EEFEQ35982925-DFDECEF7-33C2-49AE-8518-87696F0D9DF9Q36962764-E84B0721-0F28-4B7D-804B-8E304A3942FBQ37597858-B61C3234-032E-427C-9766-85AD683D0F00Q38502350-BD32AB6B-AD4F-42DA-AA5D-24BA2F5D29B8Q39365962-998CD91F-A7F4-4E00-BB49-D4209A681F4EQ39580452-8972FAED-7612-4057-8912-78C34E7719F5Q43228470-380413D6-41AD-4F25-87FA-841934ED5A3FQ46529281-53D6AB6B-2755-4B66-8959-DD1F37B99D07Q47164059-3B8273D4-BA6F-4668-9F70-D6076DF50CDEQ52608483-6EC03B75-FD46-4B41-866E-52FE04EA6501Q55347158-762C3A35-E060-42E5-8272-A05789F79E77Q55491411-D48BC49B-F107-4165-86C9-F4322336F118
P2860
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@ast
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@en
type
label
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@ast
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@en
prefLabel
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@ast
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@en
P2093
P2860
P1476
Analysis of MET genetic aberra ...... r at MD Anderson Phase I unit.
@en
P2093
Ana M Gonzalez-Angulo
David S Hong
Debora de Melo Gagliato
Denis L Fontes Jardim
Gerald Falchook
Jennifer J Wheler
Kenneth Hess
Ralph Zinner
Sarina A Piha-Paul
P2860
P304
P356
10.1016/J.CLBC.2014.06.001
P407
P577
2014-06-23T00:00:00Z